ICOS antibody (PE)

Catalog No. ABIN2663295

The PE-conjugated Hamster Monoclonal anti-ICOS antibody (Clone C398-4A) (ABIN2663295) specifically detects ICOS in FACS. The antibody is reactive with Human, Mouse and Rat samples.

Quick Overview for ICOS antibody (PE) (ABIN2663295)

Target: ICOS (Inducible T-Cell Co-Stimulator (ICOS))

Reactivity: Human, Mouse, Rat

Host: Hamster

Clonality: Monoclonal

Conjugate: This ICOS antibody is conjugated to PE

Application: Flow Cytometry (FACS)

Clone: C398-4A

Product Details anti-ICOS Antibody (PE)

Cross-Reactivity: Rhesus Monkey, Pig (Porcine)

Purification: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotype: IgG

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for ICOS

Target: ICOS (Inducible T-Cell Co-Stimulator (ICOS))

Alternative Name: CD278

Background: ICOS, also known as inducible costimulatory molecule and H4, is a 47-57 kD protein. This protein is homologous to the CD28/CTLA-4 proteins. ICOS is expressed on activated T cells and a subset of thymocytes. It is able to costimulate T cells proliferation. In addition, ICOS is involved in humoral immune responses (B cell germinal center formation). The ICOS ligand is B7h/B7RP-1 or B7-H2. ICOS stimulation has been shown to potentiate TCR-mediated IL-4 and IL-10 production and has been proposed to play a role in Th2 cell development.

Pathways: Cancer Immune Checkpoints